$8 Billion Opportunity: Inhibrx’s Experimental Cancer Drug Draws Major Interest
Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.
NOTRELOAD AI
AT&T Q1 2026: Fiber + Wireless Growth Accelerates, Guidance Holds Steady
AT&T beat Q1 expectations with higher revenue and earnings, strong customer growth, but stock fell on cash flow and outlook concerns.
Boeing Reports Much Smaller Q1 Loss Than Expected as Recovery Gains Momentum
Boeing Q1 2026: $22.2B revenue (+14%), small $7M loss. Deliveries up, backlog $695B. Shares rise as recovery continues.
BofA Turns Bullish on Twilio – Sees Strong AI Infrastructure Future
Bank of America upgraded Twilio to Buy, raised target to $190, citing AI growth, strong cash flow, and rising demand.
GE Vernova Hikes Full-Year Outlook as Power Orders Jump 71% on AI Demand
GE Vernova beat Q1 results, raised 2026 forecast as AI data centers boost electricity demand; profits, orders, and cash all up.
Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval
Kyverna’s CAR-T drug greatly improved rare SPS: patients walked 46% faster, many stopped meds; FDA filing planned 2026.